We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The FDA cleared GlaxoSmithKline's (GSK) nasal spray Veramyst April 27 for the "treatment of symptoms of seasonal and perennial rhinitis in adults and children 2 years of age and older."